Voyager Therapeutics, Inc. is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company's pipeline consists of programs for CNS indications, including advanced Parkinson's disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington's disease; Friedreich's ataxia; frontotemporal dementia/Alzheimer's disease, and severe chronic pain. The Company's clinical candidate, VY-AADC01, is an adeno-associated virus (AAV) gene therapy product candidate, for the treatment of advanced Parkinson's disease. VY-AADC01 consists of the AAV2 capsid, which has been used in multiple AAV gene therapy clinical trials for various diseases, and the cytomegalovirus promoter that drives expression of the aromatic L-amino acid decarboxylase (AADC) transgene. Its pipeline also includes VY-SOD101, VY-FXN01, VY-HTT01, VY-TAU01 and VY-NAV01.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: NASDAQ:VYGR
- CUSIP: N/A
- Web: www.voyagertherapeutics.com
- Market Cap: $494.21 million
- Outstanding Shares: 26,903,000
- 50 Day Moving Avg: $10.74
- 200 Day Moving Avg: $10.41
- 52 Week Range: $8.10 - $19.67
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -7.09
- P/E Growth: 0.00
- Annual Revenue: $8.31 million
- Price / Sales: 59.47
- Book Value: $4.05 per share
- Price / Book: 4.54
- EBIDTA: ($59,320,000.00)
- Net Margins: -712.22%
- Return on Equity: -46.15%
- Return on Assets: -32.66%
- Current Ratio: 12.23%
- Quick Ratio: 12.23%
- Average Volume: 206,402 shs.
- Beta: 3.65
- Short Ratio: 6.77
Frequently Asked Questions for Voyager Therapeutics (NASDAQ:VYGR)
What is Voyager Therapeutics' stock symbol?
Voyager Therapeutics trades on the NASDAQ under the ticker symbol "VYGR."
How were Voyager Therapeutics' earnings last quarter?
Voyager Therapeutics, Inc. (NASDAQ:VYGR) posted its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.73) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.62) by $0.11. The company had revenue of $1.18 million for the quarter, compared to the consensus estimate of $3.27 million. Voyager Therapeutics had a negative net margin of 712.22% and a negative return on equity of 46.15%. View Voyager Therapeutics' Earnings History.
Where is Voyager Therapeutics' stock going? Where will Voyager Therapeutics' stock price be in 2017?
8 brokerages have issued twelve-month price targets for Voyager Therapeutics' stock. Their forecasts range from $12.00 to $37.00. On average, they expect Voyager Therapeutics' stock price to reach $24.83 in the next year. View Analyst Ratings for Voyager Therapeutics.
What are analysts saying about Voyager Therapeutics stock?
Here are some recent quotes from research analysts about Voyager Therapeutics stock:
- 1. According to Zacks Investment Research, "Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (8/11/2017)
- 2. Cowen and Company analysts commented, "VYGR had a 6/30 cash balance of $141MM, sufficient to fund operations into 2019." (8/8/2017)
- 3. Instinet analysts commented, "We are initiating on Voyager Therapeutics (VYGR) with a Buy rating and $31 target price. We anticipate updates from the ongoing trial of VY-AADC01 confirming efficacy, safety, and framing durability/duration of effect to drive upside in the share price over the next 12 months. In addition, we believe that data and initiation of a pivotal trial in advanced Parkinson's will attract investor attention, as the direct-to-CNS delivery of an enzyme becomes increasingly viewed as a risk-reduced approach to gene therapy with a rapidly addressable $1.5bn DBS-like market opportunity in advanced PD." (3/1/2017)
Are investors shorting Voyager Therapeutics?
Voyager Therapeutics saw a decrease in short interest during the month of August. As of August 15th, there was short interest totalling 469,003 shares, a decrease of 41.6% from the July 31st total of 803,724 shares. Based on an average daily volume of 125,749 shares, the days-to-cover ratio is presently 3.7 days. Approximately 3.0% of the shares of the company are sold short.
Who are some of Voyager Therapeutics' key competitors?
Some companies that are related to Voyager Therapeutics include Cellectis S.A. (CLLS), Arena Pharmaceuticals (ARNA), Albany Molecular Research (AMRI), Intellia Therapeutics (NTLA), BeyondSpring (BYSI), Heron Therapeutics (HRTX), Enanta Pharmaceuticals (ENTA), TG Therapeutics (TGTX), Spectrum Pharmaceuticals (SPPI), Crispr Theraptc (CRSP), Editas Medicine (EDIT), WAVE Life Sciences (WVE), Abeona Therapeutics (ABEO), ImmunoGen (IMGN), AC Immune SA (ACIU), ANI Pharmaceuticals (ANIP), Inovio Pharmaceuticals (INO) and Kala Pharmaceuticals (KALA).
Who are Voyager Therapeutics' key executives?
Voyager Therapeutics' management team includes the folowing people:
- Mark J. Levin, Independent Chairman of the Board
- Steven M. Paul M.D., President, Chief Executive Officer, Director
- Jane Pritchett Henderson, Chief Financial Officer, Senior Vice President
- Robert G. Pietrusko, Senior Vice President - Regulatory Affairs
- Dinah Sah Ph.D., Chief Scientific Officer
- Kathleen Hayes, Vice President - Human Resources
- John J. Connelly, Vice President - Program and Alliance Management
- Bernard Ravina M.D., Chief Medical Officer
- Glenn F. Pierce M.D., Ph.D., Director
- Wendy L. Dixon Ph.D., Independent Director
Who owns Voyager Therapeutics stock?
Voyager Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (14.01%), Bain Capital Public Equity Management LLC (4.37%), Vanguard Group Inc. (1.60%), DAFNA Capital Management LLC (0.76%), State Street Corp (0.69%) and Northern Trust Corp (0.50%). Company insiders that own Voyager Therapeutics stock include Bernard Ravina and Steven M Paul. View Institutional Ownership Trends for Voyager Therapeutics.
Who sold Voyager Therapeutics stock? Who is selling Voyager Therapeutics stock?
Who bought Voyager Therapeutics stock? Who is buying Voyager Therapeutics stock?
Voyager Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including DAFNA Capital Management LLC, Dimensional Fund Advisors LP, HarbourVest Partners LLC, Northern Trust Corp, Bessemer Group Inc., State Street Corp, Oppenheimer & Co. Inc. and Vanguard Group Inc.. View Insider Buying and Selling for Voyager Therapeutics.
How do I buy Voyager Therapeutics stock?
Shares of Voyager Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Voyager Therapeutics' stock price today?
MarketBeat Community Rating for Voyager Therapeutics (NASDAQ VYGR)MarketBeat's community ratings are surveys of what our community members think about Voyager Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Voyager Therapeutics stock can currently be purchased for approximately $18.37.
Consensus Ratings for Voyager Therapeutics (NASDAQ:VYGR) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Hold Rating, 7 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.88)|
|Consensus Price Target: ||$24.83 (35.18% upside)|
Analysts' Ratings History for Voyager Therapeutics (NASDAQ:VYGR)
(Data available from 9/25/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|9/10/2017||Chardan Capital||Reiterated Rating||Hold||Medium|
|8/16/2017||Evercore ISI||Initiated Coverage||Outperform -> Outperform||$12.00||High|
|8/8/2017||Cowen and Company||Reiterated Rating||Buy||Low|
|7/28/2017||Stifel Nicolaus||Initiated Coverage||Buy||$20.00||High|
|3/1/2017||Instinet||Initiated Coverage||Buy -> Buy||$31.00||N/A|
|11/13/2016||Piper Jaffray Companies||Reiterated Rating||Buy||$37.00||N/A|
|5/20/2016||Wells Fargo & Company||Initiated Coverage||Outperform||N/A|
Earnings History for Voyager Therapeutics (NASDAQ:VYGR)Earnings History by Quarter for Voyager Therapeutics (NASDAQ VYGR)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/8/2017||Q2 2017||($0.62)||($0.73)||$3.27 million||$1.18 million||View||Listen|
|5/9/2017||Q1 2017||($0.54)||($0.65)||$3.70 million||$1.46 million||View||Listen|
|3/15/2017||Q4 2016||($0.46)||($0.57)||$4.15 million||$2.36 million||View||N/A|
|8/11/2016||Q2||($0.34)||($0.37)||$4.79 million||$3.72 million||View||Listen|
|5/12/2016||Q1||($0.38)||$0.29||$5.00 million||$4.83 million||View||Listen|
|3/17/2016||Q4||($0.55)||($0.67)||$5.00 million||$4.94 million||View||Listen|
Earnings Estimates for Voyager Therapeutics (NASDAQ:VYGR)
2017 EPS Consensus Estimate: ($2.69)
2018 EPS Consensus Estimate: ($2.70)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Voyager Therapeutics (NASDAQ:VYGR)
No dividend announcements for this company have been tracked by MarketBeat.com
Headline Trends for Voyager Therapeutics (NASDAQ:VYGR)
Latest Headlines for Voyager Therapeutics (NASDAQ:VYGR)
|Contrasting Voyager Therapeutics (VYGR) & GTx (GTXI)|
www.americanbankingnews.com - September 20 at 6:10 PM
|Voyager Therapeutics Appoints Matthew P. Ottmer as Chief Operating Officer|
finance.yahoo.com - September 19 at 9:29 AM
|$1.15 Million in Sales Expected for Voyager Therapeutics, Inc. (VYGR) This Quarter|
www.americanbankingnews.com - September 18 at 5:14 PM
|3 Biotech Stocks That Skyrocketed This Week: Can They Go Higher?|
finance.yahoo.com - September 17 at 9:19 AM
|Insider Selling: Voyager Therapeutics, Inc. (VYGR) Insider Sells 5,490 Shares of Stock|
www.americanbankingnews.com - September 13 at 8:50 PM
|Voyager Therapeutics, Inc. (VYGR) Insider Bernard Ravina Sells 16,470 Shares|
www.americanbankingnews.com - September 13 at 8:28 PM
|Voyager Therapeutics, Inc. (VYGR) Earns "Hold" Rating from Chardan Capital|
www.americanbankingnews.com - September 11 at 8:58 PM
|Critical Comparison: Voyager Therapeutics (VYGR) versus Merrimack Pharmaceuticals (MACK)|
www.americanbankingnews.com - September 8 at 10:30 AM
|Here's Why Voyager Therapeutics Gained as Much as 24.9% Today|
finance.yahoo.com - September 7 at 11:04 AM
|Novavax (NVAX) versus Voyager Therapeutics (VYGR) Head-To-Head Review|
www.americanbankingnews.com - September 6 at 8:26 PM
|Voyager Therapeutics, Inc. (VYGR) Receives Average Recommendation of "Hold" from Brokerages|
www.americanbankingnews.com - September 6 at 4:50 PM
|Voyager Therapeutics Announces Positive Results from Ongoing Phase 1b Trial of VY-AADC01 for Advanced Parkinson’s Disease|
finance.yahoo.com - September 6 at 10:08 AM
|Voyager Therapeutics, Inc. (VYGR) Upgraded to "Sell" at ValuEngine|
www.americanbankingnews.com - September 2 at 12:06 AM
|Voyager Therapeutics to Participate in September Investor Conferences|
feeds.benzinga.com - August 30 at 2:20 PM
|Voyager Therapeutics, Inc. (VYGR) Expected to Announce Quarterly Sales of $1.15 Million|
www.americanbankingnews.com - August 30 at 9:12 AM
| Brokerages Anticipate Voyager Therapeutics, Inc. (VYGR) to Post -$0.69 Earnings Per Share|
www.americanbankingnews.com - August 28 at 2:22 PM
|Voyager Therapeutics, Inc. (VYGR) Short Interest Down 41.6% in August|
www.americanbankingnews.com - August 28 at 1:20 AM
|Voyager Therapeutics (VYGR) versus Galapagos NV (GLPG) Critical Comparison|
www.americanbankingnews.com - August 25 at 12:22 AM
|Voyager Therapeutics, Inc. (VYGR) Research Coverage Started at Evercore ISI|
www.americanbankingnews.com - August 16 at 5:40 PM
|Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Recommendation of "Hold" from Brokerages|
www.americanbankingnews.com - August 12 at 5:02 PM
|Voyager Therapeutics, Inc. (VYGR) Lowered to Sell at Zacks Investment Research|
www.americanbankingnews.com - August 11 at 4:00 PM
|Q3 2017 EPS Estimates for Voyager Therapeutics, Inc. Decreased by Wedbush (VYGR)|
www.americanbankingnews.com - August 11 at 7:48 AM
|Edited Transcript of VYGR earnings conference call or presentation 8-Aug-17 12:30pm GMT|
finance.yahoo.com - August 10 at 9:34 AM
|Voyager Therapeutics, Inc. (NASDAQ:VYGR) Announces Earnings Results, Misses Estimates By $0.11 EPS|
www.americanbankingnews.com - August 9 at 2:34 PM
|Voyager Therapeutics, Inc. (NASDAQ:VYGR) Rating Reiterated by Cowen and Company|
www.americanbankingnews.com - August 9 at 12:38 AM
|Voyager Therapeutics Reports Second Quarter 2017 Financial Results and Corporate Highlights|
finance.yahoo.com - August 8 at 8:15 AM
|Voyager Therapeutics reports 2Q loss|
finance.yahoo.com - August 8 at 8:15 AM
|Voyager Therapeutics to Host Second Quarter 2017 Financial Results and Corporate Highlights Conference Call|
feeds.benzinga.com - August 2 at 12:38 PM
|Voyager Therapeutics, Inc. (NASDAQ:VYGR) to Release Earnings on Wednesday|
www.americanbankingnews.com - August 2 at 7:22 AM
|Comparing Voyager Therapeutics (VYGR) & Codexis (CDXS)|
www.americanbankingnews.com - July 30 at 6:24 PM
|Voyager Therapeutics, Inc. (VYGR) Research Coverage Started at Stifel Nicolaus|
www.americanbankingnews.com - July 28 at 9:06 AM
|Voyager Therapeutics, Inc. (VYGR) Given Average Rating of "Hold" by Analysts|
www.americanbankingnews.com - July 18 at 5:03 PM
|Voyager Therapeutics Announces Publication from the California Institute of Technology of a Second-|
www.nasdaq.com - July 17 at 11:30 AM
|Voyager Therapeutics Announces Publication from the California Institute of Technology of a Second-Generation Gene Therapy Capsid Demonstrating Further Enhanced Gene Transfer to the Brain|
finance.yahoo.com - July 17 at 11:30 AM
|Voyager Therapeutics, Inc. (VYGR) Lifted to "Sell" at BidaskClub|
www.americanbankingnews.com - July 13 at 10:20 PM
|Zacks Investment Research Lowers Voyager Therapeutics, Inc. (NASDAQ:VYGR) to Sell|
www.americanbankingnews.com - July 13 at 10:23 AM
|Zacks: Brokerages Anticipate Voyager Therapeutics, Inc. (VYGR) Will Announce Quarterly Sales of $3.24 Million|
www.americanbankingnews.com - June 28 at 9:51 AM
|-$0.63 EPS Expected for Voyager Therapeutics, Inc. (VYGR) This Quarter|
www.americanbankingnews.com - June 26 at 8:38 PM
|Voyager Therapeutics (VYGR) Reports Clinical Trial Update with VY-AADC01 for Advanced Parkinson’s Disease|
www.streetinsider.com - June 26 at 9:31 AM
|Voyager Therapeutics Announces Clinical Trial Update with VY-AADC01 for Advanced Parkinson’s Disease|
finance.yahoo.com - June 26 at 9:31 AM
|Voyager Therapeutics, Inc. (VYGR) Receives Consensus Rating of "Buy" from Analysts|
www.americanbankingnews.com - June 23 at 2:50 PM
|ETFs with exposure to Voyager Therapeutics, Inc. : June 19, 2017|
finance.yahoo.com - June 20 at 9:13 AM
|ETFs with exposure to Voyager Therapeutics, Inc. : June 5, 2017|
finance.yahoo.com - June 6 at 1:53 AM
|$3.24 Million in Sales Expected for Voyager Therapeutics Inc (VYGR) This Quarter|
www.americanbankingnews.com - June 2 at 1:10 PM
|Voyager Therapeutics Selects Lead Clinical Candidate for Huntington’s Disease|
finance.yahoo.com - June 2 at 6:02 AM
|-$0.63 Earnings Per Share Expected for Voyager Therapeutics Inc (VYGR) This Quarter|
www.americanbankingnews.com - May 31 at 4:22 PM
|Voyager Therapeutics Inc (VYGR) Receives Consensus Rating of "Buy" from Analysts|
www.americanbankingnews.com - May 29 at 2:58 PM
|Voyager Therapeutics Inc (VYGR) Stock Rating Upgraded by Zacks Investment Research|
www.americanbankingnews.com - May 17 at 9:38 AM
|Wedbush Weighs in on Voyager Therapeutics Inc's Q2 2017 Earnings (VYGR)|
www.americanbankingnews.com - May 12 at 7:52 AM
|Edited Transcript of VYGR earnings conference call or presentation 9-May-17 9:30pm GMT|
finance.yahoo.com - May 11 at 3:20 AM
Voyager Therapeutics (VYGR) Chart for Monday, September, 25, 2017